Coherus Oncology, Inc.
Coherus Oncology, Inc. (CHRS): 14 pipeline candidates · 1 upcoming catalyst · ~9 mo cash runway · 6 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
9.1 months
D/E 2.38 · 0% dilution
Lead: Approved
14 candidates
1 upcoming, next in ~12d
N/A
A transparent, data-derived signal for Coherus Oncology, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$207.5M
Cash
$115.5M
Quarterly Burn
$57.9M
Runway
9.1 mo
Revenue
$12.3M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (14 candidates)
| Drug | Phase |
|---|---|
| casdozokitug | Phase 2 |
| chs-1000 | Preclinical |
| chs-114 | Phase 1 |
| etrumadenant | Phase 2 |
| gsk4381562 | Preclinical |
| loqtorzi | Approved |
| srf388 | Phase 2 |
| srf617 | Phase 2 |
| tagmokitug | Phase 1 |
| toripalimab | Phase 4 |
Showing 10 of 14 candidates. Sign up for full pipeline.
Upcoming Catalysts (1)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
153
Total value held
$96.7M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 10,905,524 | $18.4M |
| blackrock, inc. | 10,365,074 | $17.5M |
| samsara biocapital, llc | 3,428,571 | $5.8M |
| geode capital management, llc | 3,121,578 | $5.3M |
| state street corp | 2,325,859 | $3.9M |
| two sigma investments, lp | 2,302,001 | $3.9M |
| alyeska investment group, l.p. | 2,250,000 | $3.8M |
| tang capital management llc | 1,886,748 | $3.2M |
| hudson bay capital management lp | 1,704,980 | $2.9M |
| panagora asset management inc | 1,459,310 | $2.5M |
Showing top 10 of 153 institutional holders of Coherus Oncology, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Coherus Oncology, Inc.'s pipeline?
Coherus Oncology, Inc. (CHRS) has 14 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Coherus Oncology, Inc.'s lead drug candidate?
Coherus Oncology, Inc.'s most advanced tracked candidate is casdozokitug (Phase 2) for Hepatocellular Carcinoma.
What is Coherus Oncology, Inc.'s next catalyst?
Coherus Oncology, Inc.'s next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: chs-114" — expected June 30, 2026.
What is Coherus Oncology, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Coherus Oncology, Inc. has approximately 9.1 months of cash runway.
What is Coherus Oncology, Inc.'s market capitalization?
Coherus Oncology, Inc.'s market capitalization is approximately $207.5M.
Get the full picture on Coherus Oncology, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.